{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 449572361
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
| image = Cediranib.svg
<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 12 to 35 hours
| excretion = 
<!--Identifiers-->
| IUPHAR_ligand = 5664
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  288383-20-0
| ATC_prefix = L01
| ATC_suffix = XE32
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NQU9IPY4K9
| PubChem = 9933475
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 491473
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8109103
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XXJWYDDUDKYVKI-UHFFFAOYSA-N
<!--Chemical data-->
| C=25 | H=27 | F=1 | N=4 | O=3
| molecular_weight = 450.505 g/mol
| smiles = Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4
}}
'''Cediranib''' (AZD-2171; tentative trade name '''Recentin''') is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |doi=10.1158/0008-5472.CAN-04-4409 |pmid=15899831 |title=AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer |journal=Cancer Research |volume=65 |issue=10 |pages=4389–400 |year=2005 |last1=Wedge |first1=S. R. |last2=Kendrew |first2=J |last3=Hennequin |first3=L. F. |last4=Valentine |first4=P. J. |last5=Barry |first5=S. T. |last6=Brave |first6=S. R. |last7=Smith |first7=N. R. |last8=James |first8=N. H. |last9=Dukes |first9=M |last10=Curwen |first10=J. O. |last11=Chester |first11=R |last12=Jackson |first12=J. A. |last13=Boffey |first13=S. J. |last14=Kilburn |first14=L. L. |last15=Barnett |first15=S |last16=Richmond |first16=G. H. |last17=Wadsworth |first17=P. F. |last18=Walker |first18=M |last19=Bigley |first19=A. L. |last20=Taylor |first20=S. T. |last21=Cooper |first21=L |last22=Beck |first22=S |last23=Jürgensmeier |first23=J. M. |last24=Ogilvie |first24=D. J. }}</ref><ref name="pmid19091548">{{cite journal |doi=10.1016/j.ejca.2008.10.022 |pmid=19091548 |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=European Journal of Cancer |volume=45 |issue=5 |pages=782–8 |year=2009 |last1=Goss |first1=Glenwood |last2=Shepherd |first2=Frances A. |last3=Laurie |first3=Scott |last4=Gauthier |first4=Isabelle |last5=Leighl |first5=N. |last6=Chen |first6=Eric |last7=Feld |first7=Ronald |last8=Powers |first8=Jean |last9=Seymour |first9=Lesley }}</ref><ref name="pmid18520296">{{cite journal |doi=10.1097/JTO.0b013e318174e910 |pmid=18520296 |title=The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies |journal=Journal of Thoracic Oncology |volume=3 |issue=6 |pages=S131–4 |year=2008 |last1=Nikolinakos |first1=Petros |last2=Heymach |first2=John V. }}</ref>

The drug is being developed by [[AstraZeneca]] as a possible anti-cancer chemotherapeutic agent for oral administration. 

== Clinical trials ==
Beginning in 2007, it underwent [[Clinical trial#Phase I|phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.

On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader [[bevacizumab]].<ref>{{cite web|title=AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer|url=http://www.astrazeneca.com/Media/Press-releases/Article/20100308--RECENTIN-did-not-meet-primary-endpoint-in-Horizon-III|accessdate=17 March 2014}}</ref> 
In 2016, AstraZeneca completed a phase III trial comparing the efficacy of cediranib alone and cediranib with [[lomustine]] to the efficacy of lomustine alone in patients with recurrent glioblastoma. The trial failed to meet its primary endpoint and survival was not extended with cediranib.<ref>{{cite journal |doi=10.1200/JCO.2012.47.2464 |pmid=23940216 |pmc=4021043 |title=Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination with Lomustine, Versus Lomustine Alone in Patients with Recurrent Glioblastoma |journal=Journal of Clinical Oncology |volume=31 |issue=26 |pages=3212–8 |year=2013 |last1=Batchelor |first1=T. T. |last2=Mulholland |first2=P. |last3=Neyns |first3=B. |last4=Nabors |first4=L. B. |last5=Campone |first5=M. |last6=Wick |first6=A. |last7=Mason |first7=W. |last8=Mikkelsen |first8=T. |last9=Phuphanich |first9=S. |last10=Ashby |first10=L. S. |last11=Degroot |first11=J. |last12=Gattamaneni |first12=R. |last13=Cher |first13=L. |last14=Rosenthal |first14=M. |last15=Payer |first15=F. |last16=Jurgensmeier |first16=J. M. |last17=Jain |first17=R. K. |last18=Sorensen |first18=A. G. |last19=Xu |first19=J. |last20=Liu |first20=Q. |last21=Van Den Bent |first21=M. }}</ref>

==Combination trials==
Findings from a federally funded, NCI-sponsored phase II clinical trial<ref>{{ClinicalTrialsGov|NCT01116648|Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer}}</ref> presented at the 50th Annual Meeting of the [[American Society of Clinical Oncology]] (May 30 - June 3, 2014, Chicago, Ill; Abstract No: LBA5500),<ref>{{cite journal |doi=10.1016/S1470-2045(14)70391-2 |pmid=25218906 |pmc=4294183 |title=Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study |journal=The Lancet Oncology |volume=15 |issue=11 |pages=1207–14 |year=2014 |last1=Liu |first1=Joyce F |last2=Barry |first2=William T |last3=Birrer |first3=Michael |last4=Lee |first4=Jung-Min |last5=Buckanovich |first5=Ronald J |last6=Fleming |first6=Gini F |last7=Rimel |first7=BJ |last8=Buss |first8=Mary K |last9=Nattam |first9=Sreenivasa |last10=Hurteau |first10=Jean |last11=Luo |first11=Weixiu |last12=Quy |first12=Philippa |last13=Whalen |first13=Christin |last14=Obermayer |first14=Lisa |last15=Lee |first15=Hang |last16=Winer |first16=Eric P |last17=Kohn |first17=Elise C |last18=Ivy |first18=S Percy |last19=Matulonis |first19=Ursula A }}</ref> show that the combination of two investigational oral drugs, [[olaparib]], a PARP inhibitor, and cediranib is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.<ref>[http://oncozine.com/profiles/blogs/combination-of-targeted-drugs-may-significantly-increase-pfs Combination of Targeted Drugs May Significantly Increase Progression-Free Survival in Women with Recurrent Ovarian Cancer, Study Shows - Onco'Zine - The International Oncology Network; June 2, 2014]</ref>

==References==
{{reflist}}

==External links==
*[https://web.archive.org/web/20070310202726/http://www.cancerline.com/cancerlinehcp/15602_15632_9_3_1.aspx AZD2171&mdash;AstraZeneca Pipeline]

{{Extracellular chemotherapeutic agents}}
{{Growth factor receptor modulators}}

[[Category:Receptor tyrosine kinase inhibitors]]
[[Category:Indoles]]
[[Category:Quinazolines]]
[[Category:Fluoroarenes]]
[[Category:Phenol ethers]]
[[Category:Pyrrolidines]]
[[Category:Experimental cancer drugs]]